Merck's vicriviroc misses Phase III endpoints

Merck & Co. Inc. (NYSE:MRK) disclosed in an investor update that it will not submit an NDA for vicriviroc to treat HIV in treatment-experienced patients at this time after it missed the primary endpoi...